A Review of Trastuzumab-Based Therapy in Patients with HER2-positive Metastatic Breast Cancer

被引：0
作者：
Church, David N. [1 ]
Price, Chris G. A. [2 ]
机构：
[1] Univ Oxford, John Racliffe Hosp, Weatherall Inst Mol Med, Headley Way, Oxford OX3 9DS, England
[2] Bristol Haematol & Oncol Ctr, Bristol BS1 8ED, Avon, England
来源：
CLINICAL MEDICINE INSIGHTS-THERAPEUTICS | 2009年 / 1卷
关键词：
breast cancer; trastuzumab; metastatic; ERBB2; HER2;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The ERBB2 or HER2 receptor is overexpressed in 25% of breast cancers and is associated with poor prognosis. Trastuzumab, a monoclonal antibody targeting HER2 has been demonstrated to improve survival when combined with chemotherapy for the treatment of HER2 overexpressing metastatic breast cancer (MBC). Further studies have endeavoured to clarify the optimum chemotherapy regimen in combination with trastuzumab for MBC and its use together with novel biological agents. This review summarises these data together with preclinical studies exploring the mechanism of trastuzumab action and causes of drug resistance. The frequent incidence of brain metastases in patients on trastuzumab is highlighted, and data on the continuation of trastuzumab following CNS and non-CNS progression reviewed.
引用
收藏
页码：557 / 570
页数：14
相关论文
共 149 条
[31]   Extended survival in women with brain Metastases from HER2 overexpressing breast cancer [J].
Church, David N. ;
Modgil, Ramayana ;
Guglani, Sam ;
Bahl, Amit ;
Hopkins, Kirsten ;
Braybrooke, Jeremy P. ;
Blair, Peter ;
Price, Chris G. A. .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2008, 31 (03) :250-254
[32]   EGF-ERBB signalling: towards the systems level [J].
Citri, Ami ;
Yarden, Yosef .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2006, 7 (07) :505-516
[33]   Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer [J].
Clayton, AJ ;
Danson, S ;
Jolly, S ;
Ryder, WDJ ;
Burt, PA ;
Stewart, AL ;
Wilkinson, PM ;
Welch, RS ;
Magee, B ;
Wilson, G ;
Howell, A ;
Wardley, AM .
BRITISH JOURNAL OF CANCER, 2004, 91 (04) :639-643
[34]   Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets [J].
Clynes, RA ;
Towers, TL ;
Presta, LG ;
Ravetch, JV .
NATURE MEDICINE, 2000, 6 (04) :443-446
[35]   Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease [J].
Cobleigh, MA ;
Vogel, CL ;
Tripathy, D ;
Robert, NJ ;
Scholl, S ;
Fehrenbacher, L ;
Wolter, JM ;
Paton, V ;
Shak, S ;
Lieberman, G ;
Slamon, DJ .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2639-2648
[36]   Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu [J].
Cooley, S ;
Burns, LJ ;
Repka, T ;
Miller, JS .
EXPERIMENTAL HEMATOLOGY, 1999, 27 (10) :1533-1541
[37]   TYROSINE KINASE RECEPTOR WITH EXTENSIVE HOMOLOGY TO EGF RECEPTOR SHARES CHROMOSOMAL LOCATION WITH NEU ONCOGENE [J].
COUSSENS, L ;
YANGFENG, TL ;
LIAO, YC ;
CHEN, E ;
GRAY, A ;
MCGRATH, J ;
SEEBURG, PH ;
LIBERMANN, TA ;
SCHLESSINGER, J ;
FRANCKE, U ;
LEVINSON, A ;
ULLRICH, A .
SCIENCE, 1985, 230 (4730) :1132-1139
[38]   Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments [J].
Dang, CT ;
Dannenberg, AJ ;
Subbaramaiah, K ;
Dickler, MN ;
Moasser, MM ;
Seidman, AD ;
D'Andrea, GM ;
Theodoulou, M ;
Panageas, KS ;
Norton, L ;
Hudis, CA .
CLINICAL CANCER RESEARCH, 2004, 10 (12) :4062-4067
[39]   Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial [J].
De Maio, Ermelinda ;
Pacilio, Carmen ;
Gravina, Adriano ;
Morabito, Alessandro ;
Di Rella, Francesca ;
Labonia, Vincenzo ;
Landi, Gabriella ;
Nuzzo, Francesco ;
Rossi, Emanuela ;
Silvestro, Pasqualina ;
Botti, Gerardo ;
Di Bonito, Maurizio ;
Curcio, Maria Pia ;
Formichelli, Franca ;
La Vecchia, Franca ;
Staiano, Maria ;
Maurea, Nicola ;
D'Aiuto, Giuseppe ;
D'Aiuto, Massimiliano ;
Thomas, Renato ;
Signoriello, Giuseppe ;
Perrone, Francesco ;
de Matteis, Andrea .
BMC CANCER, 2007, 7 (1)
[40]   Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation [J].
Diermeier, S ;
Horváth, G ;
Knuechel-Clarke, R ;
Hofstaedter, F ;
Szöllösi, J ;
Brockhoff, G .
EXPERIMENTAL CELL RESEARCH, 2005, 304 (02) :604-619
12345678910